$ORKA
Oruka Therapeutics, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020036784 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $940.0K $940.0K $900.0K
YoY Change 4.44% -12.15% -2.17%
% of Gross Profit
Research & Development $1.051M $370.0K $350.0K
YoY Change 200.29% -15.91% -52.7%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $10.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.051M $1.310M $1.250M
YoY Change -15.92% -13.25% -24.7%
Operating Profit
YoY Change
Interest Expense $2.000K $3.000K $1.000K
YoY Change 100.0% 0.0% -97.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.991M -$1.311M -$1.198M
YoY Change 66.19% -10.39% -26.23%
Income Tax $0.00 -$9.000K -$42.00K
% Of Pretax Income
Net Earnings -$1.991M -$1.302M -$1.156M
YoY Change 72.23% -9.33% -27.43%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$329.5K -$726.3K -$763.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.10M $11.00M $9.600M
YoY Change 432.29% 10.0% 18.52%
Cash & Equivalents $51.10M $11.04M $9.645M
Short-Term Investments
Other Short-Term Assets $800.0K $500.0K $300.0K
YoY Change 166.67% 40.06% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $51.90M $11.60M $9.900M
YoY Change 424.24% 12.37% 17.86%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $0.00 $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $36.00K $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $82.00K $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $51.90M $11.60M $9.900M
Total Long-Term Assets $82.00K $0.00 $0.00
Total Assets $51.98M $11.60M $9.900M
YoY Change 425.07% 11.67% 17.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $761.0K $600.0K $100.0K
YoY Change 661.0% 136.22% -50.0%
Accrued Expenses $800.0K $800.0K $1.000M
YoY Change -20.0% -11.11% 25.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.527M $1.300M $1.200M
YoY Change 27.25% 8.42% 20.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.527M $1.300M $1.200M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.500M $1.300M $1.200M
YoY Change 25.0% 8.33% 20.0%
SHAREHOLDERS EQUITY
Retained Earnings -$149.0M
YoY Change
Common Stock $199.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.46M $10.31M $8.799M
YoY Change
Total Liabilities & Shareholders Equity $51.98M $11.60M $9.900M
YoY Change 425.07% 11.54% 17.86%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q3
OPERATING ACTIVITIES
Net Income -$1.991M -$1.302M -$1.156M
YoY Change 72.23% -9.33% -27.43%
Depreciation, Depletion And Amortization $10.00K $0.00 $10.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$2.000M -$1.040M -$880.0K
YoY Change 127.27% -12.61% -43.95%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$10.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 42.06M 5.410M 570.0K
YoY Change 7278.95% 71.75%
NET CHANGE
Cash From Operating Activities -2.000M -1.040M -880.0K
Cash From Investing Activities 0.000 -10.00K 0.000
Cash From Financing Activities 42.06M 5.410M 570.0K
Net Change In Cash 40.06M 4.360M -310.0K
YoY Change -13022.58% 122.45% -80.25%
FREE CASH FLOW
Cash From Operating Activities -$2.000M -$1.040M -$880.0K
Capital Expenditures $0.00 -$10.00K $0.00
Free Cash Flow -$2.000M -$1.030M -$880.0K
YoY Change 127.27% -13.45% -43.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Operating Expenses
OperatingExpenses
3289000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3289000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
7318000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3262000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
737000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1156000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
8799000
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27000
CY2019Q4 us-gaap Stockholders Equity Other
StockholdersEquityOther
10000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-1226000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
6306000
CY2020Q2 abio Issuance Of Common Stock And Exercise Of Prefunded Warrants
IssuanceOfCommonStockAndExerciseOfPrefundedWarrants
5297000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
11000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
47000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
32000
us-gaap Share Based Compensation
ShareBasedCompensation
20000
us-gaap Share Based Compensation
ShareBasedCompensation
95000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-95000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-161000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-103000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-13000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
23000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-36000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-192000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
94000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6061000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6517000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2728000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2756000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
514000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
287000
us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
135000
us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
116000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5412000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6114000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2678000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3358000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8363000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6608000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11041000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9966000
us-gaap Interest Paid Net
InterestPaidNet
4000
us-gaap Interest Paid Net
InterestPaidNet
3000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
9000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
109000
abio Vendor Finance Agreement
VendorFinanceAgreement
273000
abio Vendor Finance Agreement
VendorFinanceAgreement
233000
abio Common Stock Offering Costs Accrued Reversal But Not Yet Paid
CommonStockOfferingCostsAccruedReversalButNotYetPaid
250000
abio Common Stock Offering Costs Accrued Reversal But Not Yet Paid
CommonStockOfferingCostsAccruedReversalButNotYetPaid
68000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y9M21D
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p>
us-gaap Revenues
Revenues
0
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24100000
CY2020Q2 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
164291
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
168695
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
164291
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
168695
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
abio Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0
CY2019 abio Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
356000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
377000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
344000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
367000
CY2013Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
5300
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P6M
CY2020Q1 abio Lease Renewal Start Date
LeaseRenewalStartDate
2020-04-01
us-gaap Operating Lease Payments
OperatingLeasePayments
45000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3M18D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25000000
CY2020Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherAccruedLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherAccruedLiabilitiesCurrent
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
31136
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
246
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
30684
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
30890
CY2020Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-09-30
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Under the February 2020 Amendment, the Company has no further rights to extend or renew this lease agreement.
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
us-gaap Lessee Operating Lease Assumptions And Judgments Allocation Of Lease And Nonlease Component
LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent
The lease includes real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
25000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
25000
us-gaap Operating Lease Payments
OperatingLeasePayments
51000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
84.50
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M21D

Files In Submission

Name View Source Status
0001564590-20-036784-index-headers.html Edgar Link pending
0001564590-20-036784-index.html Edgar Link pending
0001564590-20-036784.txt Edgar Link pending
0001564590-20-036784-xbrl.zip Edgar Link pending
abio-10q_20200630.htm Edgar Link pending
abio-20200630.xml Edgar Link completed
abio-20200630.xsd Edgar Link pending
abio-20200630_cal.xml Edgar Link unprocessable
abio-20200630_def.xml Edgar Link unprocessable
abio-20200630_lab.xml Edgar Link unprocessable
abio-20200630_pre.xml Edgar Link unprocessable
abio-ex311_7.htm Edgar Link pending
abio-ex312_8.htm Edgar Link pending
abio-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending